Abstract
Background
The accelerated vaccine development in response to the COVID-19 pandemic should lead to a vaccine being available early 2021, albeit in limited supply and possibly without full vaccine acceptance. We assessed the short-term impact of a COVID-19 immunization program with varying constraints on population health and non-pharmaceutical interventions (NPIs) needs.
Methods
A SARS-CoV-2 transmission model was calibrated to French epidemiological data. We defined several vaccine implementation scenarios starting in January 2021 based on timing of discontinuation of NPIs, supply and uptake constraints, and their relaxation. We assessed the number of COVID-19 hospitalizations averted, the need for and number of days with NPIs in place over the 2021–2022 period.
Results
An immunisation program under constraints could reduce the burden of COVID-19 hospitalizations by 9–40% if the vaccine prevents against infections. Relaxation of constraints not only reduces further COVID-19 hospitalizations (30–39% incremental reduction), it also allows for NPIs to be discontinued post-2021 (0 days with NPIs in 2022 versus 11 to 125 days for vaccination programs under constraints and 327 in the absence of vaccination).
Conclusion
For 2021, COVID-19 control is expected to rely on a combination of NPIs and the outcome of early immunisation programs. The ability to overcome supply and uptake constraints will help prevent the need for further NPIs post-2021. As the programs expand, efficiency assessments will be needed to ensure optimisation of control policies post-emergency use.
Publisher
Public Library of Science (PLoS)
Reference50 articles.
1. Keeping track of the SARS-CoV-2 vaccine pipeline;EPK Parker;Nat Rev Immunol,2020
2. Corum J, Wee S-L, Zimmer C. Coronavirus Vaccine Tracker [Internet]. N. Y. Times. [cited 2020 Oct 26]. Available from: https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html.
3. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia;DY Logunov;Lancet Lond Engl,2021
4. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK;M Voysey;Lancet Lond Engl,2021
5. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine;LR Baden;N Engl J Med,2021
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献